Display options
Cite
McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol. 2021;doi: 10.1002/ppul.25733.
McBennett, K. A., Davis, P. B., & Konstan, M. W. (2021). Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatric pulmonology, . https://doi.org/10.1002/ppul.25733
McBennett, Kimberly A, et al. "Increasing life expectancy in cystic fibrosis: Advances and challenges." Pediatric pulmonology vol. (2021). doi: https://doi.org/10.1002/ppul.25733
McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol. 2021 Oct 21; doi: 10.1002/ppul.25733. Epub 2021 Oct 21. PMID: 34672432.
Copy Download .nbib Format: NLM
Share it on

Pediatr Pulmonol. 2021 Oct 21; doi: 10.1002/ppul.25733. Epub 2021 Oct 21.

Increasing life expectancy in cystic fibrosis: Advances and challenges.

Pediatric pulmonology

Kimberly A McBennett, Pamela B Davis, Michael W Konstan

Affiliations

  1. Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  2. Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.

PMID: 34672432 DOI: 10.1002/ppul.25733

Abstract

Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.

© 2021 Wiley Periodicals LLC.

Keywords: CFTR modulators; cystic fibrosis; lung function; survival

References

  1. Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. Bethesda, Maryland. ©2020 Cystic Fibrosis Foundation. - PubMed
  2. Scotet V, Carine L'Hostis C, Claude, Férec C. The changing epidemiology of cystic fibrosis: Incidence, survival and impact of the CFTR gene discovery. Genes. 2020;11:589. - PubMed
  3. Andersen DH. Cystic fibrosis of the pancreas and it's relation to celiac disease. Am J Dis Child. 1938;56(2):344. - PubMed
  4. Di Sant'Agnese P, Darling R, Perera B, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics. 1953;12(5):549-563. - PubMed
  5. Matthews LW, Doershuk CF, Wise M, Eddy G, Nudelman H, Spector S. A therapeutic regimen for patients with cystic fibrosis. J Pediatr. 1964;65(4):558-575. - PubMed
  6. Doershuk C, Matthews L, Tucker A, Spector S. Evaluation of a prophylactic and therapeutic program for patients with cystic fibrosis. Pediatrics. 1965;36(5):675-688. - PubMed
  7. Brownell JN, Bashaw H, Stallings VA. Growth and nutrition in cystic fibrosis. Semin Respir. Crit Care Med. 2019;40(06):775-791. - PubMed
  8. Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med. 2008;14(6):574-581. - PubMed
  9. Wallace C, Hall M, Kuhn R. Pharmacologic management of cystic fibrosis. Clin Pharm. 1993;12(9):657-674. - PubMed
  10. Tran T, Van den Neucker A, Hendriks J, Forget P, Forget P. Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatr. 1998;87(5):553-558. - PubMed
  11. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328(24):1740-1746. - PubMed
  12. Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2016;Jul 14 7(7):CD005405. - PubMed
  13. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis. NEJM. 1995;332(13):848-854. - PubMed
  14. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J of Respir Crit Care Med. 2007;176(11):1084-1089. - PubMed
  15. Konstan MW, VanDevanter DR, Sawicki GS, et al. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2018;15(4):485-493. - PubMed
  16. Langenderfer B. Alternatives to Percussion and Postural Drainage. J Cardiopulm Rehabil. 1998;18(4):283-289. - PubMed
  17. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637-642. - PubMed
  18. Hebestreit H, Lands LC, Alarie N, et al. ACTIVATE-CF Study Working Group. Effects of a partially supervised conditioning programme in cystic fibrosis: an international multi-centre randomised controlled trial (ACTIVATE-CF): study protocol. BMC Pulm Med. 2018;18(1):31. - PubMed
  19. Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Cystic Fibrosis Pulmonary Guidelines Pulmonary Complications: Hemoptysis and Pneumothorax. Am J Respir Crit Care Med. 2010;182:298-306. - PubMed
  20. Davis PB. Assisted Ventilation for Patients With Cystic Fibrosis. JAMA. 1978;239(18):1851-1854. - PubMed
  21. Sood N, Paradowski LJ, Yankaskas JR. Outcomes of Intensive Care Unit Care in Adults with Cystic Fibrosis. Am J of Respir Crit Care Med. 2001;163(2):335-338. - PubMed
  22. Oud L. Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes. PLoS One. 2017;12(10):e0186770. - PubMed
  23. Spoletini G, Pollard K, Watson R, et al. Noninvasive ventilation in cystic fibrosis: Clinical indications and outcomes in a large UK adult cystic fibrosis center. Respir Care. 2020;66(3):466-474. - PubMed
  24. Yeung JC, Machuca TN, Chaparro C, et al. Lung transplantation for cystic fibrosis. J Heart Lung Transplant. 2020;39(6):553-560. - PubMed
  25. Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2018;34(3):146-151. - PubMed
  26. Reynaud QRousset, Jablonski C, Stéphanie Poupon-Bourdy S, Touzet S, Durieu I. Pregnancy outcome in women with cystic fibrosis and poor pulmonary function. J Cystic Fibr. 2020;19:80-83. - PubMed
  27. Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med. 2007;13(6):537-540. - PubMed
  28. Cystic Fibrosis Foundation Patient Registry. 2015 Annual Data Report. Bethesda, Maryland. ©2016 Cystic Fibrosis Foundation. - PubMed
  29. Thomassen M, Demko C, Kinger J, Stern R. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Amer Rev Respir Dis. 1985;131:791-796. - PubMed
  30. Thomassen M, Demko C, Doershuk C, Stern R, Klinger J. Pseudomonas Cepacia decrease in colonization in patients with cystic fibrosis. American. J Respir Dis. 1986;134:669-671. - PubMed
  31. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2015;71 Suppl 1:i1-i22. - PubMed
  32. Schechter M, Shelton B, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Amer J Respir Critl Care Med. 2001;163(6):1331-1337. - PubMed
  33. O'Connor GT, Quinton HB, Kneeland T, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003;111(4):e333-e339. - PubMed
  34. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009;155(5):634-639e1-e4. - PubMed
  35. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109(5):893-899. - PubMed
  36. McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol. 2017;52(12):1550-1557. - PubMed
  37. Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California. Chest. 2016;149:380-389. - PubMed
  38. Rho J, Ahn C, Gao A, Sawicki GS, Keller A, Jain R. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018;Oct 15198(8):1055-1063. - PubMed
  39. McGarry ME, Williams WA, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol. 54. 2019;Suppl 3:S74-S83. - PubMed
  40. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med. 1997;337(14):963-969. - PubMed
  41. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatrics. 2008;153(2):PS4-S14. - PubMed
  42. Martiniano SL, Elbert AA, Farrell PM, et al. Outcomes of infants born during the first 9 years of CF newborn screening in the United States: a retrospective Cystic Fibrosis Foundation Patient Registry cohort study. Pediatr Pulmonol. Published online September 1, 2021. doi:10.1002/ppul.25658 - PubMed
  43. Farrell PM, Kosorok MR, Rock MJ, et al. and the Wisconsin Cystic Fibrosis Neonatal Screening Study Group Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics. 2001;107(1):1-13. - PubMed
  44. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;Oct 15 53(RR-13):1-36. - PubMed
  45. Farrell PM, Rock MJ, Baker MW. The impact of the CFTR gene discovery on the cystic fibrosis diagnosis, counseling, and preventative therapy. Genes. 2020;11(4):401-416. - PubMed
  46. Chudleigh J, Chinnery H. Psychological impact of NBS for CF. Int J Neonatal Screen. International journal of neonatal screening. 2020;306(2):27. - PubMed
  47. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. Genet Med. 2016;19(1):36-44. - PubMed
  48. Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M. The spectrum of CFTR variants in nonwhite cystic fibrosis patients. J Mol Diag. 2016;18(1):39-50. - PubMed
  49. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005;147(3):S37-S41. - PubMed
  50. Campbell PW, White TB. Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. J Pediatr. 2005;147(3):S2-S5. - PubMed
  51. Shum BOV, Bennett G, Navilebasappa A, Kumar RK. Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: a case report. BMC Pediatr. 2021;21(1):154. - PubMed
  52. Baker MW, Atkins AE, Cordovado SK, Hendrix M, Earley MC, Farrell PM. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genet Med. 2015;18(3):231-238. - PubMed
  53. Farrell PM, White TB, Derichs N, Castellani C, Rosenstein BJ. Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. J Pediatr. 2017;181:S16-S26. - PubMed
  54. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. NEJM. 2011;365(18):1663-1672. - PubMed
  55. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. NEJM. 2015;373(3):220-231. - PubMed
  56. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. NEJM. 2017;377(21):2013-2023. - PubMed
  57. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. NEJM. 2019;381(19):1809-1819. - PubMed
  58. Shteinberg M, Taylor-Cousar JL. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev. 2020;29(155). - PubMed
  59. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic gibrosis. Pediatr Res. 1997;41(2):161-165. - PubMed
  60. Daines CL, Morgan WJ. The future of highly effective modulator therapy in cystic fibrosis. Amer J Respir Crit Care Med. 2021;203(12):1453-1455. - PubMed
  61. Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Amer J Respir Crit Care Med. 2015;192(7):836-842. - PubMed
  62. Guimbellot JS, Baines A, Paynter A, et al. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. J Cyst Fibros. 2021;20(2):213-219. - PubMed
  63. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107-118. - PubMed
  64. Flume PA, Biner RF, Downey DG, et al. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021;9(7):733-746. - PubMed
  65. Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020;19(1):68-79. - PubMed
  66. Flume PA, Wainwright CE, Tullis E, et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018;17(1):83-88. - PubMed
  67. Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Ann Am Thorac Soc. 2020;17(2):147-154. - PubMed
  68. Davies JC, Cunningham S, Harris WT, et al. Rosenfeld M. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet. Respir Med. 2016;4(2):107-115. - PubMed
  69. Rosenfeld M, Cunningham S, Harris WT, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros. 2019;18(6):838-843. - PubMed
  70. Rosenfeld M, Wainwright CE, Higgins M, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545-553. - PubMed
  71. Megalaa R, Gopalareddy V, Champion E, Goralski JL. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use. Pediatr Pulmonol. 2019;54:54. - PubMed
  72. Munce D, Lim M, Akong K. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Pediatr Pulmonol. 2020;55(12):3381-3383. - PubMed
  73. Nichols AL, Davies JC, Jones D, Carr SB. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev. 2020;35:99-102. - PubMed
  74. Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. Published online April 2021;20:835-836. doi:10.1016/j.jcf.2021.03.018 - PubMed
  75. Dagenais RVE, Su VC, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review. J Clin Med. 2020;10(1):23. - PubMed
  76. Trimble AT, Donaldson SH. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros. 2018;17(2):e13-e16. - PubMed
  77. McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496-1503. - PubMed
  78. Rubin JL, O'Callaghan L, Pelligra C, et al. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Ther Adv Respir Dis. 2019;13:1-23. - PubMed
  79. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. NEJM Published online June 26, 2021. - PubMed

Publication Types